Use of pramipexole for the treatment of addictive disorders
AssigneePharmacia & Upjohn Company
InventorsRobert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander
Life of this patent
Estimating the term…
Abstract
This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.
Claims11
A method of treating or enhancing the treatment of a disorder selected from, addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising:
- administering a therapeutically effective, nontoxic dose of pramipexole, the compound 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (−)-enantiomer thereof, or the administration of an effective amount, its dihydrochloride, or its dihydrochloride-(H2O) and derivatives and or pharmaceutically acceptable salts thereof to a patient.
A method for treating or enhancing the treatment of a disorder selected from:
- addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof where the dose is either about 0.01-10.0 mg/day, about 0.125-6 mg/day, or about 0.375-5 mg/day or 0.75 to 4.5 mg/day to a patient in need of treatment of these disorders.
The use of pramipexole or its pharmaceutically acceptable salts in the manufacture of a medicament to treat:
- addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction where the medicament is in the form of:
- a tablet, where the tablet is in the size of a 0.125, 0.250, 0.50, 1.0, 1.25 or 1.5 mg tablet, a chewable form where the chewable form contains 0.075, 0.125, 0.250, 0.50 or 1.0 mg per square of chewable gum like substance;
- a transdermal patch;
- or an inhaler;
- where the patch or inhaler administers blood levels to the patient comparable to the tablets or gum described herein.
Dependencies are inferred from the claim text.